Nanobiotix

Equities

NANO

FR0011341205

Biotechnology & Medical Research

Real-time Euronext Paris Other stock markets 04:40:54 2024-06-28 am EDT			5-day change	1st Jan Change
4.644 ^EUR	-6.03%		+17.21%	-30.06%

Jun. 25	ADRs End Higher; Nanobiotix S.A. Climbs 12%	DJ
Jun. 25	Stifel Initiates Nanobiotix with Buy Rating	MT

Nanobiotix Announces Revenue Results for the Fourth Quarter and Full Year Ended December 31, 2013

January 31, 2014 at 01:33 pm EST

Nanobiotix announced revenue results for the fourth quarter and full year ended December 31, 2013. For the quarter, the company reported revenues of EUR 48,667 against EUR 46,409 a year ago.

For the year, the company reported revenues of EUR 190,068 against EUR 74,153 a year ago.

Latest news about Nanobiotix

ADRs End Higher; Nanobiotix S.A. Climbs 12%	Jun. 25	DJ
Stifel Initiates Nanobiotix with Buy Rating	Jun. 25	MT
Nanobiotix: well oriented on broker's comments	Jun. 25	CF
NANOBIOTIX : Stifel initiates buy coverage	Jun. 25	CF
Transcript : Nanobiotix S.A. - Special Call	Jun. 18
Nanobiotix Announces New Data Showing Disease Control and Tumor Response in Patients Treated with RT-Activated NBTXR3 Followed By anti-PD-1 For 2l+ R/M HNSCC Naïve or Resistant to Prior anti-PD-1 Therapy	Jun. 03	CI
Transcript : Nanobiotix S.A. - Special Call	Jun. 02
Nanobiotix S.A. Announces Presentation of New Data from Phase 1 Immunotherapy Program at the 2024 Annual Meeting of the American Society for Clinical Oncology	May. 28	CI
Transcript : Nanobiotix S.A., Q1 2024 Earnings Call, May 22, 2024	May. 22
Nanobiotix: strategy update, share price declines	May. 22	CF
Nanobiotix to Transfer Phase 3 Head and Neck Cancer Study Sponsorship	May. 21	MT
Nanobiotix Announces Progress in Global NBTXR3 Development Collaboration Highlighting Robust Pipeline and Pathway to Long-Term Growth	May. 21	CI
Nanobiotix to Proceed to Phase 2 Trial of Lung Cancer Treatment	May. 14	MT
Nanobiotix Announces US FDA Protocol Acceptance for New Randomized Phase 2 Study Evaluating Nbtxr3 for Patients with Stage Three Lung Cancer	May. 14	CI
Transcript : Nanobiotix S.A., Q4 2023 Earnings Call, Apr 25, 2024	Apr. 25
Nanobiotix S.A. Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 24	CI
Nanobiotix S.A. Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 24	CI
Nanobiotix completes escalation portion of 2020-0123 study	Apr. 03	CF
Nanobiotix Completes Dose Escalation Segment of Phase 1 Study Targeting Non-Small Cell Lung Cancer	Apr. 02	MT
Nanobiotix Announces Completion of Phase 1 Dose Escalation and NBTXR3 Recommends Phase 2 Dose for the Treatment of Inoperable, Recurrent Lung Cancer in Patients Amenable to Re-Irradiation	Apr. 02	CI
Nanobiotix Gets $20 Million Milestone Payment in Phase 3 Trial for Potential Head, Neck Cancer Drug	Jan. 30	MT
Nanobiotix: targets achieved for NANORAY-312	Jan. 30	CF
Nanobiotix Gets $20 Million Milestone Payment from Janssen	Jan. 30	MT
Nanobiotix: transfer of NBTXR3 rights in Asia	Dec. 27	CF
Nanobiotix Partner Transfers Asian Commercialization Rights for Oncology Therapy to Johnson & Johnson Unit	Dec. 27	MT

Chart Nanobiotix

Duration

Period

More charts

Company Profile

Nanobiotix is a pioneer and leader in nanomedicine that has developed a revolutionary approach to the treatment of cancer. The company focuses its effort on the development of its products portfolio entirely patented, NanoXray, innovation based on the physical mode of action of nanoparticles that, under the action of radiation, allow maximizing the absorption of X-rays inside the cancer cells without increasing the dose received by the surrounding healthy tissue. NanoXray products are compatible with standard radiotherapy treatments and are intended to potentially treat a wide variety of cancers via multiple routes of administration. The company's resources are primarily devoted to the development of its lead product candidate: NBTXR3, which is the product of its proprietary oncology platform and has already achieved market authorization in Europe for the treatment of patients with soft tissue sarcoma under the brand name Hensify®.

Sector

Biotechnology & Medical Research

Calendar

2024-09-03 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Nanobiotix

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

4.942 EUR

Average target price

11.68 EUR

Spread / Average Target

+136.34%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
NANOBIOTIX	-30.06%	249M
MODERNA, INC.	+21.85%	46.44B
LONZA GROUP AG	+37.97%	39.1B
IQVIA HOLDINGS INC.	-8.05%	38.76B
ALNYLAM PHARMACEUTICALS, INC.	+29.04%	31.24B
CELLTRION, INC.	-13.75%	25.8B
ICON PUBLIC LIMITED COMPANY	+10.65%	25.9B
MEDPACE HOLDINGS, INC.	+38.43%	13.12B
BIO-TECHNE CORPORATION	-6.92%	11.32B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-12.29%	10.68B

Other Biotechnology & Medical Research